IL156435A0 - Crystallization of igf-1 - Google Patents

Crystallization of igf-1

Info

Publication number
IL156435A0
IL156435A0 IL15643502A IL15643502A IL156435A0 IL 156435 A0 IL156435 A0 IL 156435A0 IL 15643502 A IL15643502 A IL 15643502A IL 15643502 A IL15643502 A IL 15643502A IL 156435 A0 IL156435 A0 IL 156435A0
Authority
IL
Israel
Prior art keywords
igf
crystallization
relates
candidate
indirect
Prior art date
Application number
IL15643502A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL156435A0 publication Critical patent/IL156435A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
IL15643502A 2001-02-09 2002-02-01 Crystallization of igf-1 IL156435A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26797701P 2001-02-09 2001-02-09
US28707201P 2001-04-27 2001-04-27
PCT/US2002/003156 WO2002064627A2 (en) 2001-02-09 2002-02-01 Crystallization of igf-1

Publications (1)

Publication Number Publication Date
IL156435A0 true IL156435A0 (en) 2004-01-04

Family

ID=26952796

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15643502A IL156435A0 (en) 2001-02-09 2002-02-01 Crystallization of igf-1
IL156435A IL156435A (en) 2001-02-09 2003-06-12 Formation of IGF-1

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL156435A IL156435A (en) 2001-02-09 2003-06-12 Formation of IGF-1

Country Status (20)

Country Link
US (8) US7084240B2 (zh)
EP (3) EP1358209B1 (zh)
JP (2) JP4489352B2 (zh)
KR (1) KR100872613B1 (zh)
CN (1) CN100439397C (zh)
AT (2) ATE439378T1 (zh)
AU (1) AU2002255508B2 (zh)
BR (1) BR0207422A (zh)
CA (1) CA2431033A1 (zh)
DE (3) DE60217066T4 (zh)
DK (2) DK1358209T3 (zh)
ES (2) ES2331150T3 (zh)
HK (1) HK1060138A1 (zh)
HU (1) HUP0500733A3 (zh)
IL (2) IL156435A0 (zh)
MX (1) MXPA03007042A (zh)
NZ (3) NZ548358A (zh)
PL (1) PL374181A1 (zh)
WO (1) WO2002064627A2 (zh)
ZA (1) ZA200304900B (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072780A2 (en) * 2001-03-14 2002-09-19 Genentech, Inc. Igf antagonist peptides
EP1435986B1 (en) * 2001-09-18 2008-01-02 Bioexpertise, Llc Igf-binding protein-derived peptide
US6914049B2 (en) 2001-09-18 2005-07-05 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
US20070219767A1 (en) * 2003-05-06 2007-09-20 Carter Daniel C Atomic coordinates of albumin drug complexes and method of use of pharmaceutical development
EP1684705A4 (en) * 2003-11-03 2008-02-20 New Century Pharmaceuticals ALBUMIN BINDING FACILITIES FOR THE EVALUATION OF MEDICAMENTAL INTERACTION EFFECTS AND METHOD FOR ASSESSING OR DESIGNING MEDICAMENT BASED ON THEIR ALBUMIN BONDING PROPERTIES
EP1706128B1 (en) * 2003-12-08 2010-07-21 CPEX Pharmaceuticals, Inc. Pharmaceutical compositions and methods for insulin treatment
WO2006001911A2 (en) * 2004-05-06 2006-01-05 Genentech, Inc. Crystal structure of the hepatocyte growth factor beta chain and methods of use
WO2005108424A1 (en) * 2004-05-06 2005-11-17 Genentech, Inc. Crystal structure of the complex of hepatocyte growth factor bata chain with met receptor and methods of use
UA103758C2 (ru) 2004-07-19 2013-11-25 Биокон Лимитед Конъюгаты олигомеров инсулина, их композиции и применение
EP1848812A4 (en) * 2004-10-01 2011-11-09 Life Technologies Corp SUPPLY BUFFERS, SYSTEMS AND METHODS FOR THE IN VITRO SYNTHESIS OF BIOMOLECULES
US7556776B2 (en) * 2005-09-08 2009-07-07 President And Fellows Of Harvard College Microfluidic manipulation of fluids and reactions
BRPI0812768A2 (pt) * 2007-06-08 2014-12-02 Massachusetts Inst Technology Igf para o tratamento de síndrome de rett e transtornos sinápticos.
WO2009026172A2 (en) * 2007-08-17 2009-02-26 The Regents Of The University Of California New approach for designing diabetes drugs
CN101139391B (zh) * 2007-08-21 2012-07-25 陈志南 Cd147胞外区晶体结构及应用
WO2009134395A2 (en) 2008-04-28 2009-11-05 President And Fellows Of Harvard College Microfluidic device for storage and well-defined arrangement of droplets
AU2010275010B2 (en) * 2009-07-22 2013-10-24 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (IGF-1) having amino acid substitution at position 59
WO2011011071A2 (en) * 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (igf-1)
US20120266263A1 (en) * 2009-10-14 2012-10-18 Mount Sinai School Of Medicine Method of treating memory disorders and enhancing memory using igf-ii compounds
EP2830625A1 (en) * 2012-03-28 2015-02-04 Merck Sharp & Dohme Corporation Insulin-like growth factor-1 receptor inhibitors
KR101711584B1 (ko) * 2012-12-18 2017-03-02 재단법인 의약바이오컨버젼스연구단 변형된 eprs 단백질의 결정 구조 및 이의 결정화 방법
EP3082841B1 (en) * 2013-12-19 2021-03-17 Puretein Bioscience, LLC Methods for treating an animal
US20240050455A1 (en) * 2020-06-01 2024-02-15 Loma Linda University Health Methods of treatment of a cytokine storm

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US577276A (en) * 1897-02-16 Quarter-saver iv
US589867A (en) * 1897-09-14 Clothes-line hanger
US4672108A (en) * 1981-12-07 1987-06-09 Hoffmann-La Roche Inc. Crystalline human leukocyte interferon
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
JPH0720993B2 (ja) * 1985-08-22 1995-03-08 グロペップ プロプライエタリー リミテッド 生長因子
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
US4833233A (en) * 1987-08-20 1989-05-23 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Human serum albumin crystals and method of preparation
SE8703625D0 (sv) 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4876242A (en) * 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
EP0346429B1 (en) * 1987-12-24 1994-12-28 Gropep Pty. Ltd. Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2)
US5470828A (en) * 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
DE68905203T2 (de) * 1988-02-05 1993-07-22 Ciba Geigy Ag Verwendung von igf i zur herstellung eines praeparates fuer die behandlung von nierenkrankheiten.
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
GB8920381D0 (en) 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
US5028224A (en) * 1990-01-09 1991-07-02 Kimberly-Clark Corporation Apparatus for intermittently depositing particulate material in a substrate
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5681814A (en) 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
SE9100099D0 (sv) 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
ES2101865T3 (es) * 1991-08-01 1997-07-16 Genentech Inc Igf-1 para mejorar el estado neural.
US5126314A (en) * 1991-09-06 1992-06-30 Eastman Kodak Company Mixture of dyes for black dye donor for thermal color proofing
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
JPH07508025A (ja) 1992-05-08 1995-09-07 トーマス・ジェファーソン・ユニバーシティ インスリン様増殖因子（ｉｇｆ−１）類似体
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
EP0668914B1 (en) 1992-06-09 2000-08-16 Chiron Corporation Crystallization of m-csf
ATE187889T1 (de) 1992-06-12 2000-01-15 Cephalon Inc Vorbeugung und behandlung der peripheren neuropathie
NZ255461A (en) 1992-08-20 1996-12-20 Biotechnology & Biolog Science Specific binding molecules for insulin-like-growth-factor-1 (igf-1), antigens capable of generating them and their use in enhancing igf-1 activity
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
JPH08500123A (ja) 1993-01-25 1996-01-09 ザ ベス イスラエル ホスピタル アソシエイション Ｉｇｆ−ｉ感受性細胞のバリヤー特性の修飾方法，診断方法及びスクリーニング方法
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5534488A (en) * 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
US5407810A (en) 1993-08-20 1995-04-18 Genentech, Inc. Aqueous multiple-phase isolation of polypeptide
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
SE9402370D0 (sv) 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
US5597893A (en) * 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
SE9501472D0 (sv) 1995-04-21 1995-04-21 Pharmacia Ab Truncated IGF-I
DK0833847T3 (da) 1995-06-22 2003-12-29 Biogen Inc Krystaller af fregmenter af CD40-ligand og deres anvendelse
US5948751A (en) * 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
JP3417230B2 (ja) * 1996-09-25 2003-06-16 信越化学工業株式会社 型取り母型用光硬化性液状シリコーンゴム組成物
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
US5898028A (en) * 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
CA2294833A1 (en) 1997-07-03 1999-01-14 Smithkline Beecham Corporation Crystal structures of anti-factor ix fab fragments and methods of use for peptidomimetic design
US5876242A (en) * 1997-07-21 1999-03-02 Williams; Hugh D. Remote battery extension apparatus
WO1999038011A1 (en) 1998-01-21 1999-07-29 The Brigham And Women's Hospital, Inc. Circulating insulin-like growth factor-i and prostate cancer risk
AU6515499A (en) 1998-10-16 2000-05-08 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
AU2000239309A1 (en) 2000-03-29 2001-10-08 Dgi Biotechnologies Llc Insulin and igf-1 receptor agonists and antagonists
CA2449290A1 (en) 2001-06-07 2002-12-12 F. Hoffmann-La Roche Ag Mutants of igf binding proteins and methods of production of antagonists thereof
US20040137518A1 (en) * 2002-01-31 2004-07-15 Lambert Millard Hurst CRYSTALLIZED PPARa LIGAND BINDING DOMAIN POLYPEPTIDE AND SCREENING METHODS EMPLOYING SAME
JP3680801B2 (ja) * 2002-02-27 2005-08-10 株式会社デンソー 回転電機の巻線接合方法

Also Published As

Publication number Publication date
EP1772464A2 (en) 2007-04-11
IL156435A (en) 2009-09-22
DK1358209T3 (da) 2007-05-07
NZ548358A (en) 2008-04-30
DE60233359D1 (de) 2009-09-24
MXPA03007042A (es) 2004-05-24
ATE349469T1 (de) 2007-01-15
US20060287510A1 (en) 2006-12-21
CN1703425A (zh) 2005-11-30
NZ548359A (en) 2007-11-30
KR20040064610A (ko) 2004-07-19
WO2002064627A3 (en) 2003-07-31
US7354769B2 (en) 2008-04-08
ES2278020T3 (es) 2007-08-01
KR100872613B1 (ko) 2008-12-09
US7433788B2 (en) 2008-10-07
HUP0500733A2 (hu) 2005-10-28
US7596455B2 (en) 2009-09-29
US20060276397A1 (en) 2006-12-07
CA2431033A1 (en) 2002-08-22
ATE439378T1 (de) 2009-08-15
JP2009215299A (ja) 2009-09-24
EP1358209B1 (en) 2006-12-27
JP2005503329A (ja) 2005-02-03
DK1772464T3 (da) 2009-12-14
PL374181A1 (en) 2005-10-03
US20020165155A1 (en) 2002-11-07
ES2331150T3 (es) 2009-12-22
US20050215477A1 (en) 2005-09-29
HUP0500733A3 (en) 2010-01-28
ZA200304900B (en) 2005-07-27
US20060281905A1 (en) 2006-12-14
EP1772464A3 (en) 2007-10-03
BR0207422A (pt) 2005-04-19
EP1358209A2 (en) 2003-11-05
EP1801120A1 (en) 2007-06-27
DE60217066D1 (de) 2007-02-08
HK1060138A1 (en) 2004-07-30
US7084240B2 (en) 2006-08-01
JP4489352B2 (ja) 2010-06-23
US20060287235A1 (en) 2006-12-21
US20060293507A1 (en) 2006-12-28
US20060270839A1 (en) 2006-11-30
WO2002064627A2 (en) 2002-08-22
EP1772464B1 (en) 2009-08-12
AU2002255508B2 (en) 2008-04-03
US7238658B2 (en) 2007-07-03
CN100439397C (zh) 2008-12-03
US7297763B2 (en) 2007-11-20
NZ526672A (en) 2006-10-27
DE60217066T2 (de) 2007-07-12
DE60217066T4 (de) 2010-07-01

Similar Documents

Publication Publication Date Title
IL156435A0 (en) Crystallization of igf-1
WO2003040309A3 (en) Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
HK1089323A1 (en) A method and system for holding session continuity
AR030504A1 (es) Peptidos ciclicos selectivos
DK1316801T3 (da) Sammensætninger og fremgangsmåder til detektion og behandling af sygdomme og tilstande, som er relateret til kemokinreceptorer
DE69918946D1 (de) Rezeptoren für il-18
RS50966B (sr) Agonisti pyy i njihova upotreba
ATE491024T1 (de) Xylanase-varianten mit veränderter sensitivität gegenüber xylanase-hemmstoffen
WO2003104410A3 (en) ENZYMES
WO2005117936A3 (en) Method for enhancing or inhibiting insulin-like growth factor-i
WO1999057140A3 (en) Growth-associated protease inhibitor heavy chain precursor
AU2002343794A1 (en) Data relay, method for determining transmission destination of acquired request, and program for realizing the method by computer
MXPA04001730A (es) Metodo para determinacion de multiples analitos.
DK1363944T3 (da) Höjaffinitetsantagonister for ELR-CXC-kemokiner
SI1565490T1 (sl) Partnerji vezave holo transkobalaminov in njihovauporaba v kobalaminskem testu
DE69820483D1 (de) Antimicrobielles, mit getränken kompatibles schmiermittel für förderanlagen
WO2002102847A1 (fr) Nouveau ligand et son adn
DK0923644T3 (da) G-koblet receptor, der udviser selektiv selektivitet for ATP
WO2000003015A3 (en) Human transport protein homologs
WO2004070389A8 (en) Assay for protein isoforms
WO2003063769A3 (en) Vesicle-associated proteins
DE69929580D1 (de) Einfügungsmechanismus mit Kugelverriegelung, für Einschaltwiderstand
AU3169599A (en) Method for screening substance promoting oligomerization of receptor protein molecules
WO2004012037A3 (en) On-the-fly mpeg trick mode processing
WO2002057874A3 (en) System and process for routing information in a data processing system